Glucocorticoid and Breviscapine Combination Therapy Versus Glucocorticoid Alone on Sudden Sensorineural Hearing Loss in
- PDF / 328,949 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 55 Downloads / 244 Views
ORIGINAL RESEARCH
Glucocorticoid and Breviscapine Combination Therapy Versus Glucocorticoid Alone on Sudden Sensorineural Hearing Loss in Patients with Different Audiometric Curves Zhong Zheng . Ying Shen . Liang Xia . Hongmin Wu . Huiqun Zhou . Xulan Tang . Lili Meng . Hui Wang . Yaqin Wu . Haibo Shi . Shankai Yin . Yanmei Feng . Zhengnong Chen Received: July 30, 2020 / Accepted: September 23, 2020 Ó Springer Healthcare Ltd., part of Springer Nature 2020
ABSTRACT Introduction: We aimed to retrospectively analyze the therapeutic outcomes of using glucocorticoid combined with a vasodilator, breviscapine, versus glucocorticoid alone in patients with sudden sensorineural hearing loss (SSNHL) and to explore the impact on different audiometric curves. Methods: Data from 154 patients were collected between January 2017 and December 2018. Patients received treatments of either glucocorticoid combined with breviscapine (GC ? Bre) or glucocorticoid alone (GC). These two groups were stratified into low frequencies SSNHL (LF-SSNHL), high frequencies SSNHL (HF-SSNHL), all frequencies SSNHL (AF-SSNHL), and total deafness SSNHL (TD-SSNHL) subgroups according to their corresponding audiograms. The hearing level was evaluated by pure tone audiometry, and hearing recovery was Zhong Zheng and Ying Shen contributed equally to this work. Z. Zheng Y. Shen L. Xia H. Wu H. Zhou X. Tang L. Meng H. Wang Y. Wu H. Shi S. Yin Y. Feng (&) Z. Chen (&) Department of Otolaryngology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, No. 600, Yishan Road, Xuhui District, Shanghai 200233, China e-mail: [email protected]. Chen e-mail: [email protected]
calculated by comparing the pure tone average (PTA) at pretreatment and 4 weeks after therapy. Results: Hearing recovery was significantly greater for GC ? Bre than GC-only treatment in the AF-SSNHL and TD-SSNHL subgroups (P \ 0.05) and to a lesser extent in the LFSSNHL and HF-SSNHL subgroups (P [ 0.05). Logistic regression analysis also showed a favorable outcome for SSNHL in the GC ? Bre group (odds ratio 2.848, P \ 0.05). Conclusion: Treating SSNHL using glucocorticoid combined with breviscapine could be more beneficial than using glucocorticoid alone, especially for patients with AF-SSNHL and TDSSNHL. Trial Registration Number: ChiCTR1800017 0072 Keywords: Breviscapine; Glucocorticoid; Pure tone average; Vasodilator; Sudden sensorineural hearing loss
Adv Ther
Key Summary Points Why carry out this study? American and Chinese medical guidelines both agree on using glucocorticoid to treat SSNHL, yet they disagree on the use of vasodilators. The study explores whether a vasodilator (breviscapine) should be recommended for the treatment of SSNHL, and on the basis of the result, provides insight into the etiology and pathophysiological mechanisms of the disease. What was learned from the study? The effects of breviscapine are positively significant in treating severe or complete SSNHL in conjunction with glucocorticoid. Treating SSNHL using glucocorticoid com
Data Loading...
